Welcome to our dedicated page for Magenta Therapeutics news (Ticker: mgta), a resource for investors and traders seeking the latest updates and insights on Magenta Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Magenta Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Magenta Therapeutics's position in the market.
Magenta Therapeutics (Nasdaq: MGTA) announced promising results from a Phase 2 trial of MGTA-145 and plerixafor for stem cell mobilization in multiple myeloma patients at the ASCO Annual Meeting. All 15 patients achieved the primary endpoint of 2 million CD34+ cells per kg in up to two days, with 12 achieving it in one day. The median collection was 6.3 million cells per kg. Transplanted patients showed successful engraftment and quick recovery of blood cells. The regimen was well tolerated, with mild side effects. Final data is expected by the end of 2021.
Magenta Therapeutics (Nasdaq: MGTA) will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 4:40 p.m. ET. A live webcast will be available on their website, with a replay accessible for 90 days post-event. Magenta focuses on developing novel medicines utilizing the curative potential of stem cell transplants for patients with blood cancers, genetic disorders, and autoimmune diseases. The company combines expertise in stem cell biology with a unique business model to transform immune resetting treatments.
Magenta Therapeutics (Nasdaq: MGTA) has announced that its CEO, Jason Gardner, will participate in fireside chats at two investor conferences this month. These events are the Cowen 2nd Annual Virtual Oncology Innovation Summit on May 20 at 10:40 a.m. ET and the Oppenheimer Rare & Orphan Disease Summit on May 21 at 2:55 p.m. ET. Interested parties can access live webcasts on the company's website, with replays available for 90 days post-event. Magenta aims to advance stem cell transplant therapies for various blood cancers and genetic diseases.
Magenta Therapeutics (Nasdaq: MGTA) announced a private placement agreement to sell approximately 9.6 million shares of common stock, aiming for gross proceeds of $86.4 million at $9.00 per share. The offering is led by institutional investors and is expected to close on May 14, 2021, pending customary conditions. Proceeds will be used for general corporate purposes and working capital. The shares are not registered under the Securities Act, but a resale registration statement will be filed with the SEC. Magenta focuses on innovative therapies in stem cell transplants for various diseases.
Magenta Therapeutics (Nasdaq: MGTA) announced positive preliminary results from its Phase 2 trial of MGTA-145 plus plerixafor for multiple myeloma. The trial showed that all 10 patients mobilized and collected the targeted stem cells, achieving the endpoint within two days, with a median collection of 5.4 million CD34+ stem cells per kg. The regimen was well tolerated, with mild side effects reported. Magenta plans to file an IND for MGTA-117 aimed at AML and MDS patients. The results will be presented at the EHA Congress, June 9-17, 2021.
Magenta Therapeutics (Nasdaq: MGTA) reported its financial results for Q1 2021, highlighting progress in clinical programs. The company is optimistic about upcoming Phase 2 trial results for MGTA-145 in Multiple Myeloma and plans to submit an IND for MGTA-117. Cash reserves as of March 31, 2021, totaled $132.3 million, expected to fund operations into Q1 2023. Research and development expenses decreased to $11.7 million, while general administration costs slightly fell to $7.0 million. The net loss for Q1 2021 stood at $17.5 million, an improvement from the previous year.
Magenta Therapeutics (NASDAQ: MGTA) has announced that President and CEO Jason Gardner will speak at the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference on April 1, 2021, at 1:00 p.m. ET. The discussion, titled Key Advances in Solid Organ and Stem Cell Transplants - Expanding the Market and Moving Away from Lifelong Immunosuppression, will focus on revolutionary developments in stem cell transplants. A live webcast will be available on the company's website, with a replay accessible for 90 days after the event.
Magenta Therapeutics (NASDAQ: MGTA) announced data presentations at the EBMT 2021 annual meeting, emphasizing advancements in stem cell mobilization and conditioning therapies. Significant findings include the oral presentation of MGTA-145, which showed effective mobilization of hematopoietic stem cells combined with plerixafor, and the poster presentation of MGTA-117, a targeted conditioning agent for stem cell transplants. MGTA-117 is anticipated to enter clinical trials in mid-2021, addressing a critical need for safer conditioning regimens in treating acute myeloid leukemia and myelodysplastic syndromes.
Magenta Therapeutics (NASDAQ: MGTA) will present at the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021, at 10:00 a.m. ET. The event will be held virtually, and a live webcast can be accessed through the Magenta Therapeutics website, with a replay available for 90 days afterward.
Magenta is focused on developing novel therapies to harness the curative potential of stem cell transplants for patients with blood cancers, genetic disorders, and autoimmune diseases. Based in Cambridge, Mass, the company combines expertise in stem cell biology with regulatory proficiency.
Magenta Therapeutics (Nasdaq: MGTA) reported its Q4 and full-year 2020 financial results, highlighting advancements in its clinical programs, particularly with MGTA-145 and MGTA-117. The company is executing two Phase 2 trials for MGTA-145 in blood cancers and plans another trial for sickle cell disease. Financially, cash equivalents stood at $148.8 million, expected to fund operations into 2023. R&D expenses decreased to $12.3 million, while net loss was $18.2 million, an improvement from last year.
FAQ
What is the market cap of Magenta Therapeutics (mgta)?
